Ananda Developments PLC (AQSE:ANA) recently hired a contract research specialist in Australia to glean key insights on potential chronic pain treatment, MRX1. This evaluation, known as a pharmacokinetic (PK) study, aims to understand how MRX1 moves through the body—how it's absorbed, distributed, metabolised, and eventually excreted. The results will help researchers determine the safest and most effective dose for patients. PK studies are crucial in developing new medicines as they guide dosing decisions and ensure safety. To learn more, check out our detailed explainer [here].
Advertisement Go to Proactive UK Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com